Microneedle Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030

The global healthcare industry is witnessing a transformative shift in drug delivery methods, particularly in the field of transdermal drug administration. The conventional approach of hypodermic needles for injections has long been associated with various risks such as needle injuries, pain perception, and limitations of skin transport barriers. In this context, microneedle arrays (MNA) have emerged as an ideal solution for minimally invasive and painless drug delivery through the skin, bypassing the stratum corneum and disrupting the traditional drug delivery landscape.

Microneedles Minimize Patient Trypanophobia, Paving the Way for Immunisation Programs

Microneedle drug delivery offers several advantages, including faster onset, improved efficacy, and higher patient compliance. By providing therapeutic benefits and delivering reproducible results with pinpoint accuracy and minimal variability in bioavailability, microneedles are revolutionizing drug delivery methods. One of the significant advantages of microneedles is their ability to minimize patient trypanophobia, which is the fear of needles. This aspect is increasing adoption rates in the paediatrics segment and bolstering mass immunisation programs. With higher efficiency in drug delivery control compared to other transdermal methods, microneedles are shaping the future of drug administration.

Microneedle Companies Collaborate with Vaccine Manufacturers to Ensure Success

Leading players in the microneedle drug delivery market, such as NanoPass Technologies, are collaborating with immunotherapy companies to leverage their proprietary MicronJet technology in the development of affordable, effective, and safe COVID-19 vaccines. Other prominent companies in the market include 3M, Microdermics, Zosano Pharma Corporation (ZSAN), Nitto Denko Corporation, Becton, Dickinson and Company, Vaxxas Pty Ltd, Valeritas (Zealand Pharma A/S), Corium, Inc., TheraJect, Inc., LTS Lohmann Therapie-Systeme AG, and Alza Corporation. The shared intellectual property between these companies and vaccine manufacturers is expected to play a pivotal role in ensuring successful drug delivery.

Versatility of Microneedle Arrays Enables Innovative Drug Delivery Solutions

The demand for therapies where active substances are not effectively absorbed through oral administration has driven the innovation of newer nanoparticle and microparticle drug encapsulation technologies. Transdermal administration, especially with ovalbumin as the most common protein antigen for immunisation studies using microneedle arrays, has shown immense promise. Microneedles have also garnered significant interest in the cosmetics and diagnostics industries, with clinical trials being conducted for wearable epidermal diagnostic devices. The unique attributes of microneedle arrays allow them to open up limitless opportunities for rectal, oral, ocular, and buccal drug delivery.

Low Manufacturing Cost Fuels Popularity of Hollow Microneedle Arrays

The microneedle drug delivery market offers various fabrication options, including dissolving, hollow, hydrogel, and solid microneedle arrays. While solid microneedles made from silicon or metal are well-established and have a longer product lifespan, polymer microneedle arrays have witnessed significant growth in recent years. Hollow microneedle arrays are particularly favored due to their precise drug control, low cost, and ease of manufacturing. These attributes contribute to their popularity and widespread use in the microneedle drug delivery market.

As the global healthcare industry continues to emphasize innovation and patient-centric drug delivery methods, microneedle arrays are set to play a pivotal role in revolutionizing transdermal drug administration.